Yoichi Araki

Mr. Yoichi Araki

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2012 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
KSKazuhiro Saito
Kazuhiro Saito
JLJoseph Ledsam
Joseph Ledsam
SSSteven Sourbron
Steven Sourbron
JOJun Otaka
Jun Otaka
YAYoichi Araki
Yoichi Araki
KTKoichi Tokuuye
Koichi Tokuuye
Purpose: To evaluate liver function obtained by tracer-kinetic modeling of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data acquired with a routine gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced protocol. Materials and Methods: Data were acquired from 25 cases of nonchronic liver disease and 94 cases of cirrhosis. DCE-MRI was performed with a dose of 0.025 mmol/kg Gd-EOB-DTPA injected at 2 mL/sec. A 3D breath-hold sequence acquired 5 volumes of 72 slices each: precontrast, double arterial phase, portal phase, and 4-minute postcontrast. Regions of interest (ROIs) were selected semiautomatically in the aorta, portal vein, and whole liver on a middle slice. A constrained dual-inlet two-compartment uptake model was fitted to the ROI curves, producing three parameters: intracellular uptake rate (UR), extracellular volume (Ve), and arterial flow fraction (AFF). Results: Median UR dropped from 4.46 10−2 min−1 in the noncirrhosis to 3.20 in Child–Pugh A (P = 0.001), and again to 1.92 in Child–Pugh B (P < 0.0001). Median Ve dropped from 6.64 mL 100 mL−1 in the noncirrhosis to 5.80 in Child–Pugh A (P = 0.01). Other combinations of Ve and AFF changes were not significant for any group. Conclusion: UR obtained from tracer kinetic analysis of a routine DCE-MRI has the potential to become a novel index of liver function. J. Magn. Reson. Imaging 2013;37:1109–1114.

5 January 2017 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
TMTomohisa Moriya
Tomohisa Moriya
KSKazuhiro Saito
Kazuhiro Saito
YTYu Tajima
Yu Tajima
THTaiyo Leopoldo Harada
Taiyo Leopoldo Harada
YAYoichi Araki
Yoichi Araki
KTKoichi Tokuuye
Koichi Tokuuye
To evaluate the usefulness of differentiation of histological grade in hepatocellular carcinoma (HCC) using three-dimensional (3D) analysis of apparent diffusion coefficient (ADC) histograms retrospectively. The subjects consisted of 53 patients with 56 HCCs. The subjects included 12 well-differentiated, 35 moderately differentiated, and nine poorly differentiated HCCs. Diffusion-weighted imaging (b-values of 100 and 800 s/mm2) were obtained within 3 months before surgery. Regions of interest (ROIs) covered the entire tumor. The data acquired from each slice were summated to derive voxel-by-voxel ADCs for the entire tumor. The following parameters were derived from the ADC histogram: mean, standard deviation, minimum, maximum, mode, percentiles (5th, 10th, 25th, 50th, 75th, and 90th), skew, and kurtosis. These parameters were analyzed according to histological grade. After eliminating steatosis lesions, these parameters were re-analyzed. A weak correlation was observed in minimum ADC and 5th percentile for each histological grade (r = –0.340 and r = –0.268, respectively). The minimum ADCs of well, moderately, and poorly differentiated HCC were 585 ± 388, 411 ± 278, and 235 ± 102 × 10−6 mm2/s, respectively. Minimum ADC showed significant differences among tumor histological grades (P = 0.009). The minimum ADC of poorly differentiated HCC and that of combined well and moderately differentiated HCC were 236 ± 102 and 437 ± 299 × 10−6 mm2/s. The minimum ADC of poorly differentiated HCC was significantly lower than that of combined well and moderately differentiated HCC (P = 0.001). The sensitivity and specificity, when a minimum ADC of 400 × 10−6 mm2/s or lower was considered to be poorly differentiated HCC, were 100 and 54%, respectively. After exclusion of the effect of steatosis, the sensitivity and specificity did not change, although the statistical differences became strong (P < 0.0001). Minimum ADC was most useful to differentiate poorly differentiated HCC in 3D analysis of ADC histograms.

7 June 2024 in Medicine
Verified
Journal Article
Open access
TKTatsuya Kakegawa
Tatsuya Kakegawa
KSKatsutoshi Sugimoto
Katsutoshi Sugimoto
KSKazuhiro Saito
Kazuhiro Saito
DYDaisuke Yunaiyama
Daisuke Yunaiyama
YAYoichi Araki
Yoichi Araki
Tkao ItoiTkao Itoi
Tkao Itoi
To investigate changes in skeletal muscle mass and fat fraction in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) undergoing treatment with Semaglutide for 6months. This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM. Body weight, metabolic parameters, liver enzymes, fibrosis markers, skeletal muscle index (cm2/m2), and fat fraction (%) at the L3 level using the two-point Dixon method on magnetic resonance imaging (MRI), as well as liver steatosis and liver stiffness assessed using MRI-based proton density fat fraction (MRI-PDFF) and MR elastography, respectively, were prospectively examined before and 6 months after semaglutide administration. The mean age of the patients was 53 years and 47.6% were females. The median liver steatosis-fraction (%) and skeletal muscle steatosis-fraction values (%) significantly decreased (22.0 vs 12.0; P = .0014) and (12.8 vs 9.9; P = .0416) at baseline and 6 months, respectively, while maintaining muscle mass during treatment. Semaglutide also dramatically reduced hemoglobin A1c (%) (6.8 vs 5.8, P = .0003), AST (IU/L) (54 vs 26, P < .0001), ALT (IU/L) (80 vs 34, P = .0004), and γ-GTP (IU/L) levels (64 vs 34, P = .0007). Although not statistically significant, Body weight (kg) (79.9 vs 77.4), body mass index (BMI) (kg/m2) (28.9 vs 27.6), and liver stiffness (kPa) (28.9 vs 27.6) showed a decreasing trend. Fibrosis markers such as M2BPGi, type IV collagen, and skeletal muscle area did not differ. Semaglutide demonstrated favorable effects on liver and skeletal muscle steatosis, promoting improved liver function and diabetic status.

20 April 2018
Verified
Journal Article
Open access
PDF file
KSKazuhiro Saito
Kazuhiro Saito
JLJoseph Ledsam
Joseph Ledsam
KSKatsutoshi Sugimoto
Katsutoshi Sugimoto
SSSteven Sourbron
Steven Sourbron
YAYoichi Araki
Yoichi Araki
KTKoichi Tokuuye
Koichi Tokuuye
Dynamic contrast-enhanced MRI (DCE-MRI) can measure the changes in tumor blood flow, vascular permeability and interstitial and intravascular volume. The objective was to evaluate the efficacy of DCE-MRI in prediction of Barcelona Clinic Liver Cancer (BCLC) staging B or C hepatocellular carcinoma (HCC) response after treatment with transcatheter arterial chemoembolization (TACE) followed by sorafenib therapy. Sorafenib was administered four days after TACE of BCLC staging B or C HCC in 11 patients (21 lesions). DCE-MRI was performed with Gd-EOB-DTPA contrast before TACE and three and 10 days after TACE. DCE-MRI acquisitions were taken pre-contrast, hepatic arterial-dominant phase and 60, 120, 180, 240, 330, 420, 510 and 600 seconds post-contrast. Distribution volume of contrast agent (DV) and transfer constant Ktrans were calculated. Patients were grouped by mRECIST after one month or more post-TACE into responders (complete response, partial response) and non-responders (stable disease, progressive disease). DV was reduced in responders at three and 10 days post-TACE (p = 0.008 and p = 0.008 respectively). DV fell in non-responders at three days (p = 0.025) but was not significantly changed from pre-TACE values after sorafenib. Sensitivity and specificity for DV 10 days post-TACE were 88% and 77% respectively. DV may be a useful biomarker for early prediction of therapeutic outcome in intermediate HCC.

16 March 2021 in Journal of the Belgian Society of Radiology
Verified
Journal Article
Open access
PDF file
RMRyuhei Masuno
Ryuhei Masuno
DYDaisuke Yunaiyama
Daisuke Yunaiyama
YSYukiko Shishido-Hara
Yukiko Shishido-Hara
DYDaisuke Yoshimaru
Daisuke Yoshimaru
CMChifumi Maruyama
Chifumi Maruyama
KSKazuhiro Saito
Kazuhiro Saito
Solitary fibrous tumors (SFTs) are rare and can be misdiagnosed because of their various radiological appearances. To clarify the characteristic MRI findings of SFTs by analyzing their radiological-pathological correlation. Nine consecutive patients with SFT who underwent magnetic resonance imaging (MRI) prior to surgery were analyzed. Eight patients underwent contrast-enhanced MRI, and three underwent dynamic MRI. Radiological-pathological correlation analysis, co-occurrence matrix, run-length matrix, and histogram analysis were performed to assess the relationship between pathological findings T1- and T2-weighted images (T1-WI and T2-WI). All nine lesions ranged in size from 20 to 36 mm. Seven lesions were located in the superior portion of the retrobulbar space found outside of the muscle cone, and two lesions in the inferior portion were located within it. No significant correlation was observed between the amount of collagenous tissue and the qualitative evaluation of the signal on T1-WI and T2-WI. Kurtosis on T2-WI was significantly correlated with the amount of collagenous tissue (ρ = –0.97, p < 0.0001) and endothelial cells (ρ = –0.49, p = 0.0479). Kurtosis in the histogram analysis on T2WI showed a strong correlation with the amount of collagenous tissue.

17 January 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
MYMika Yasutomi
Mika Yasutomi
KSKazuhiro Saito
Kazuhiro Saito
YAYoichi Araki
Yoichi Araki
KSKatsutoshi Sugimoto
Katsutoshi Sugimoto
DYDaisuke Yoshimaru
Daisuke Yoshimaru
MIMasanori Ishida
Masanori Ishida
Background: Sarcopenia is a clinically important complication of chronic liver disease (CLD), but its underlying mechanisms may differ according to disease etiology. Quantitative MRI biomarkers, including proton density fat fraction (PDFF) and magnetic resonance elastography (MRE), may help characterize etiology-specific patterns of muscle loss. This study aimed to explore etiology-specific associations between MRI-derived biomarkers and sarcopenia, with a particular focus on metabolic dysfunction-associated steatohepatitis (MASH) and viral hepatitis. Methods: This retrospective single-center study included 131 CLD patients (77 with MASH, 54 with viral hepatitis) who underwent MRI, including PDFF and MRE. Sarcopenia was defined by L2 skeletal muscle index thresholds (<42 cm2/m2 for men, <38 cm2/m2 for women). Muscle identification was performed by automatic threshold-based segmentation by a single observer. Multivariable logistic regression analyses incorporating interaction terms were performed to evaluate whether associations between MRI biomarkers and sarcopenia differed by etiology. Results: Sarcopenia was present in 56% of patients. In the overall cohort, older age (OR = 1.05, p = 0.01), lower PDFF (OR = 0.93, p = 0.03), and lower liver stiffness (OR = 0.51, p = 0.006) were independently associated with sarcopenia. A significant interaction between BMI and disease etiology was observed (p = 0.02). Subgroup analyses suggested that in MASH, sarcopenia was associated with aging, hepatic fat depletion, and lower stiffness. In contrast, in viral hepatitis, it tended to be associated with higher stiffness and lower BMI. Conclusions: MRI-derived hepatic fat and stiffness reflect distinct etiologic patterns of sarcopenia in CLD—metabolically depleted in MASH and fibrosis-related in viral hepatitis. These findings suggest that sarcopenia in MASH and viral hepatitis may reflect different underlying phenotypic patterns, highlighting the importance of considering disease etiology in imaging-based sarcopenia assessment. The results should be interpreted as hypothesis-generating and warrant validation in prospective studies.